As we celebrate the 5th anniversary of our BTK inhibitor’s approval, we’re proud to share that over 140,000 patients worldwide have been treated with this medicine across five different indications. Our commitment to expanding access and advancing cancer care remains at the heart of our mission. Today, our BTK inhibitor stands as the cornerstone of our hematology leadership, improving outcomes for patients with certain blood cancers in over 70 markets. Watch the video to learn more. #BloodCancer #BTKi #PatientsFirst
About us
BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter) and Facebook.
- Website
-
http://www.beigene.com
External link for BeiGene
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Cambridge, MA
- Type
- Public Company
- Founded
- 2010
- Specialties
- targeted therapy, immuno-oncology, hematology, oncology, and cancer
Locations
Employees at BeiGene
-
Andrew Harmon
Clinical recruiter at BeiGene
-
Roger Ralph TSCHOPP M.D., M.Sc.
Senior Medical Director, Global Medical Affairs at BeiGene
-
Scott Carter
VP, Associate General Counsel, Business Development at BeiGene
-
Alex Emanuel
Healthcare marketer, commercial operations and analytics professional
Updates
-
BeiGene reposted this
Today BeiGene unveiled our proposed company name change to BeOne Medicines Ltd., reaffirming our mission to unite the global community against cancer. The new name is part of a broader strategic growth plan that has enabled the Company’s fast rise to global leadership since its inception in 2010. Read my latest LinkedIn article for more background.
-
Today we unveiled our proposed name change to BeOne Medicines Ltd. Reaffirming our mission to unite the global community against cancer. Read the press release for full details: https://bit.ly/48Oxfyg
-
'I'm extremely proud to be part of this company because I know what we are doing is having a huge impact worldwide.' Our colleague, Gabrielle McEntee, shares her inspiration and motivation for working at BeiGene. Watch the video to discover more.
-
BeiGene announces third quarter 2024 financial results and corporate updates. Read the press release for full details. https://bit.ly/48Ty7BY
-
Did you know lung cancer is the second most common type of cancer worldwide? This Lung Cancer Awareness Month and every day, we stand united with patient groups and partners like American Lung Association and GO2 for Lung Cancer who work tirelessly to defeat lung cancer and support those affected by this disease. Learn more about lung cancer here: https://bit.ly/4hnMv9r #LungCancerAwarenessMonth #Cancer #PatientCare
-
-
As this season of Light The Night walks draw to a close, we’re inspired by the impact we’ve made together in support of The Leukemia & Lymphoma Society’s mission to end blood cancer. BeiGene was honored to serve as the National Presenting Sponsor of Survivorship and Hope, with colleagues walking alongside patients, families and communities nationwide to bring light to the darkness of cancer. Through nearly 100 events and the dedication of nearly 100,000 participants, this movement raised critical awareness and funds. With over $1.5 million contributed through our team efforts and sponsorship, we’re helping fuel LLS’s work to advance research, support patients and improve access to care. Watch the video to learn more about our journey together. #LightTheNight #TeamBeiGene #PatientsFirst
-
We’re in Houston this week with a poster at SITC 2024 highlighting preclinical data for our IL-15 prodrug. We designed this investigational molecule to remain inactive in circulation and become active at the tumor site, with the hope of killing cancer cells and reducing potential side effects. Read the scientific abstract here: https://bit.ly/4hyS9Wc #SITC2024
-
#News for #Investors and #Media: We are a month away from the biggest hematology event of the year, #ASH24. Learn more about how we are progressing our #hematology innovation and addressing the needs of patients facing B-cell malignancies: https://bit.ly/3YVOcT9
-
-
Did you know stomach cancer is the 5th most common cancer worldwide? We believe awareness is key to empowering individuals to make informed health decisions. This Stomach Cancer Awareness Month, join us to spread the word, share the knowledge, and ultimately save lives through raising awareness. #StomachCancerAwarenessMonth
Similar pages
Browse jobs
Stock
BGNE
NASDAQ
20 minutes delay
$189.23
-4.06 (-2.101%)
- Open
- 187.79
- Low
- 186.16
- High
- 191.45
Data from Refinitiv
See more info on